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Transmission of Lassa virus (family
Arenaviridae) from its natural rodent reservoir to
humans can cause hemorrhagic fever, a clinical
syndrome associated with high death rates.
Lassa fever is endemic in West Africa and has
been reported from Sierra Leone, Guinea,
Liberia, and Nigeria (1-4). The geographically
restricted occurrence of the disease is not well
understood as its rodent host (Mastomys species)
is prevalent in much larger areas of sub-Saharan
Africa. The importation of Lassa virus into other
regions, for example by travelers, is rare, with
only a few cases documented (5-9). Although
imported disease often raises public concern
because of the possibility of human-to-human
transmission; the highly pathogenic nature of the
virus; and the lack of an effective, safe therapy,
the actual risk for infection from an imported
case appears to be low (5,7), and adequate
guidelines have been published for disease
management in patients and contacts (5,10).
Arenaviruses can be divided phylogeneti-
cally, serologically, and geographically into two
major complexes: the Old World complex (e.g.,
Lassa virus, lymphocytic choriomeningitis virus
[LCMV]) and the New World complex (e.g.,
Tacaribe virus, Junin virus, Machupo virus) (11).
Isolates of Lassa virus also differ in their genetic,
serologic, and pathogenic characteristics (11-13).
This variability is evidenced by the poor cross-
complement fixation and cross-neutralization
among Lassa virus isolates of different geo-
graphic origins (3,14). Serologic differences were
demonstrated by testing a panel of Lassa virus-
specific monoclonal antibodies against many
Lassa virus isolates (13).
The single-stranded arenavirus genome
consists of a small (S) and a large (L) RNA
fragment, sizes 3.4 kb and 7 kb, respectively. The
S RNA encodes the viral glycoprotein precursor
protein (GPC) and the nucleoprotein (NP). The L
RNA encodes the viral polymerase and a small,
zinc-binding (Z) protein. Sequencing of the
complete S RNA of two Lassa virus strains,
originating from Sierra Leone (strain Josiah) (15)
and Nigeria (strain Nigeria) (16), as well as
sequencing of short S RNA fragments of
additional isolates (e.g., strain LP from Nigeria)
(11,17,18) showed considerable genetic
Imported Lassa Fever in Germany:
Molecular Characterization of a New
Lassa Virus Strain
Stephan Günther, Petra Emmerich, Thomas Laue, Olaf Kühle,
Marcel Asper, Annegret Jung, Thomas Grewing,
Jan ter Meulen, and Herbert Schmitz
Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Germany
Address for correspondence: Stephan Günther, Bernhard-
Nocht-Institut für Tropenmedizin, Bernhard-Nocht-Strasse
74, D-20359 Hamburg, Federal Republic of Germany; Fax:
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has not been reported. Viral S RNA isolated from the patient’s serum was amplified and
sequenced. A long-range reverse transcription polymerase chain reaction allowed
amplification of the full-length (3.4 kb) S RNA. The coding sequences of strain AV
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Figure 1. Map of West Africa and travel history of the
patient before the onset of febrile illness (day 0).
Countries in which Lassa fever is endemic (1-4) are
underlined.
differences. Sequence analysis of the full-length
S RNA of a large number of isolates has been
complicated by technical problems such as the
necessity to produce enough virus in cell culture
for direct cloning (15,16) or localization of
conserved regions within the S RNA for
polymerase chain reaction (PCR) primers (18).
We report the isolation and sequence
characterization of a new Lassa virus strain from
a traveler who imported the virus into Germany.
This novel strain originates from an area of West
Africa where Lassa fever has not yet been
reported. To facilitate molecular analysis of new
Lassa virus isolates, a long-range reverse
transcription (RT)-PCR was established. The
primers bind to highly conserved RNA termini
and allow amplification of full-length S RNA
directly from serum.
Methods
The Patient
A 23-year-old German woman became ill with
fever and flulike symptoms after traveling
through three West African countries (Figure 1).
In Abidjan, Côte D’Ivoire, she visited the
outpatient department of Centre Hospitalier
Universitaire de Cocody, where her illness was
diagnosed as malaria. She returned to Germany
on day 6 of illness and was hospitalized at the
Diakonie Hospital at Schwäbisch Hall. After the
diagnoses of malaria and bacterial infection were
ruled out, the patient was transferred on day 9 of
illness to the department of tropical diseases at
the Missionsärztliche Klinik in Würzburg, where
she was noted to have fever, pharyngitis,
diarrhea, and pleural effusion. Lassa fever was
suspected, and serum was sent to the Bernhard-
Nocht-Institut, Hamburg, where Lassa virus
infection was diagnosed by PCR and virus
isolation. Despite immediate ribavirin treat-
ment and intensive care, the patient’s clinical
condition deteriorated, and she died on day 14
of illness with hemorrhage, organ failure, and
encephalopathy (19).
Virus Isolation and Detection by
Immunofluorescence and Immunoblot
In the biosafety level 4 facility, Vero cells
grown in 10 mL of Leibowitz medium were
injected with 1 mL, 0.1 mL, 0.01 mL, and 0.001
mL of serum. The cell culture was examined daily
by immunofluorescence for Lassa virus infection
as well as morphologic changes. Cells were
harvested, spread onto immunofluorescence
slides, air-dried, and acetone-fixed. Immunofluo-
rescence was performed by using Lassa virus NP-
specific monoclonal antibody L2F1 (20) (dilution
of 1:50) and fluorescein isothiocyanate-labeled
anti-mouse immunoglobulin (Ig)G diluted 1:60
(Dianova, Hamburg, Germany ).
For immunoblot analysis, cells were har-
vested and pelleted by centrifugation. The cell
pellet was lysed in SDS loading buffer and boiled
for 5 min. Total cell lysate was separated in an
sodium dodecyl sulfate (SDS)-15% polyacryla-
mide gel, and proteins were transferred to
nitrocellulose membrane (Schleicher & Schuell,
Germany). Lassa virus Z protein was detected by
chemiluminescence with polyclonal chicken anti-
Z serum (dilution 1:5,000) and peroxidase-
labeled anti-chicken IgY (dilution 1:2,000)
(Dianova) as secondary antibody.
RT-PCR of S RNA
Virus RNA was isolated from 140 µL of serum
or cell culture supernatant of Lassa virus and
LCMV-infected Vero and L cells, respectively, by
using the QIAamp Viral RNA kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions (elution of RNA in 50  µL of buffer).
For reverse transcription of the full-length S
RNA, purified RNA (3-6 µL) was incubated with
20 pmol of RT primer (CGCACCGDGGATCCTAG
GC) in an 8-µL assay at 70°C for 15 minutes. The468 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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mixture was quickly chilled on ice and then
centrifuged. A 19-µL reaction premix containing
8 µL RNA-primer mix, 50 mM Tris-HCl (pH 8.3),
75 mM KCl, 3 mM MgCl2, 10 mM DTT, and 500
µM dNTP was incubated at 50°C for 2 minutes.
Then 200 units (1 µL) Superscript II reverse
transcriptase (Life Technologies, Karlsruhe,
Germany) and a drop of mineral oil were added.
The reaction was run with the following
temperature profile: 50°C for 30 minutes, 55°C
for 5 minutes, 50°C for 20 minutes, 60°C for 1
minute, and 50°C for 10 minutes. The enzyme
was inactivated at 70°C for 15 minutes. RNA was
removed by adding 2 units (1 µL) RNase H (Life
Technologies) and incubating at 37°C for 20
minutes. cDNA derived from full-length S RNA
was amplified by using the Expand High Fidelity
PCR System (Roche Molecular Biochemicals,
Mannheim, Germany) with a hot start. A 45-µL
reaction premix containing 1 µL of cDNA, 1X
reaction buffer with 1.5 mM MgCl2, 200 µM
dNTP, and 0.3 µM primers PCR1 to PCR4 in
different combinations (PCR1, tatggcgcgcCGCAC
CGDGGATCCTAGGC; PCR2, tatggcgcgcCGCAC
CGAGGATCCTAGGCATT; PCR3, tatggcgcgcCG
CACCGGGGATCCTAGGCAAT; PCR4, tatggcgc
gcCGCACCGGGGATCCTAGGCTT; PCR5, tatgg
cgcgcCGCACCGDGGATCCTAGGCWWT; heter-
ologous sequences to facilitate cloning via AscI in
lower case) was overlaid with 2 drops of oil and
heated to 55°C. Subsequently, 5 µl of enzyme
mixture containing 2.6 units Taq and Pwo
polymerase in 1X reaction buffer with 1.5 mM
MgCl2 was added. PCR was run for 40 cycles with
94° for 1 minute, 55°C for 1.5 minutes, and 72°C
for 3 minutes with an increment of 2 minutes
after every 10 cycles in a Robocycler (Stratagene,
La Jolla, California).
In a separate PCR, a 340-bp fragment of the S
RNA was amplified by using Superscript One-
Step RT-PCR System (Life Technologies) and
primers 36E2 (ACCGGGGATCCTAGGCATTT)
and 80F2 (ATATAATGATGACTGTTGTTCTTT
GTGCA) as described previously (18).
Sequence Determination
PCR products were purified by using the
QIAquick PCR purification kit (Qiagen) and were
directly sequenced with the BigDye Terminator
AmpliTaq kit (Applied Biosystems, Weiterstadt,
Germany). Extension products were separated
on an ABI 377 automated sequencer (Applied
Biosystems). The 340-bp fragment was sequenced
by using primers 36E2 and 80F2. The full-length
S RNA amplification product of independent RT-
PCRs was pooled, and plus and minus strands
were sequenced by the following primers
(numbers denote the position of the 5'-nucleotide
of the primer in the genomic sequence of Lassa
virus S RNA, strain Josiah; the sequences of LV-
SJ and LV-SAV primers are derived from strain
Josiah and strain AV, respectively): LV-SJ 1-plus
(GCACCGGGGATCCTAGGCATTTTTGGTTGC);
LV-SJ 359-plus (GGACTAGAACTGACCTTGACC
AACAC); LV-SAV 834-plus (GCACATTCACGTGG
ACACTGTCAGA); LV-SAV 1032-plus (TGAAAT
CTGAAGCACAAATGAGCAT); LV-SAV 1883-plus
(GTGATTCAAGAAGCTTCTTTATGTC); LV-SAV
2372-plus (AGATTTTGTAGAGTATGTTT CATA);
LV-SJ 2937-plus (TGCACTTAATGGCCTTTCTG
TTCT); LV-SAV 479-minus (GGTGGAAAGTTGA
GATTAT GCTCAT); LV-SJ 991-minus (CATGTC
ACAAAATTCCTCATCATG); LV-SAV 1906-minus
(ACATAAAGAAGCTTCTTGAATCACA); LV-SAV
1955-minus (ATTGAGGCGCTCCCCCGGAATA
TGG); LV-SJ 2618-minus (CTAAATATGATTGAC
ACCAAGAAAAG); LV-SJ 3092-minus (AATCAA
GCGGTCAACAATCTTGTTGA); and LV-SJ 3402-
minus (CGCACAGTGGATCCTAGGCTATTGGA
TTGC). Each nucleotide position was sequenced
by at least two different primers. The overlapping
sequences were identical, and no sequence
ambiguities were observed.
Phylogenetic Analysis
Phylogenetic analysis was performed with
the NP gene fragment for which the largest set of
arenavirus sequence data exists, at position
1724-2349 of the genomic S RNA of Lassa Josiah
(11). NP gene sequences were aligned for Lassa
AV and the following arenavirus strains (virus,
GenBank/EMBL accession number): Tacaribe,
M20304; Ippy, U80003; Mopeia AN20410,
U80005; Mopeia AN21366, M33879; Mobala
3076, AF012530; Mobala 3051, U80006; Mobala
3099, U80007; Lassa LP, U80004; Lassa Nigeria,
X52400; Lassa Josiah, J04324; LCMV Armstrong,
M20869; LCMV WE; M22138; and LCMV MaTu-
MX, Y16308. Full-length NP and GPC gene
sequences were analyzed for Lassa strains
Josiah, Nigeria, and AV, and for Mopeia
AN21366. Phylogenetic analysis was performed
by using programs of the PHYLIP 3.57c package
(21). A gap was treated as a single mutation
event. Distance matrix calculation and neighbor-
joining (NJ) analysis were conducted with theVol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 469
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Figure 2. Detection of Lassa AV in infected Vero
cells. (A) Immunofluorescence with NP-specific
monoclonal antibody L2F1 40 hours after injection
of the serum. (B) Immunoblot analysis with Z
protein-specific antiserum.
programs DNADIST and NEIGHBOR, and
maximum likelihood (ML) analysis was con-
ducted with the DNAML program. Analyses were
performed with default settings on a bootstrapped
dataset (100 replicates).
Results
Origin and Isolation of the
New Lassa Virus Strain
The exact geographic origin of the virus and
the mode and date of transmission could not be
determined. During the incubation period, which
can last up to 3 weeks (22), the patient visited
Ghana, Côte D’Ivoire, and Burkina Faso
(Figure 1). Therefore, the virus originated from
one of these West African countries, where Lassa
fever has not been reported.
The virus grew rapidly in Vero cells. Fifteen
hours after inoculation, few cells were positive,
and after 40 hours virtually all cells were infected
in cultures injected with  0.1 mL serum as tested
by immunofluorescence. In contrast to previous
Lassa virus isolations in Vero cells (23), no
substantial cytopathic effects were seen. Whether
this observation is due to technical variables
(such as inoculation dose or culture duration) or
reflects a biologic feature of the isolate is unclear.
Immunofluorescence with an NP-specific mono-
clonal antibody showed the speckled, cytoplasmic
pattern typical of Lassa virus NP (13,20) (Figure
2A). Isolation of a Lassa virus was further
confirmed by immunoblot analysis of strain AV-
infected cells using Lassa virus Z protein-specific
antibody. An 11-kDa Z protein was demonstrated
(Figure 2B) as has recently been detected in
Lassa Josiah-infected cells (24).
RT-PCR for Amplification of Full-Length S RNA
To improve and simplify molecular analysis
of new Lassa virus isolates, a protocol for reverse
transcription and PCR amplification of the full-
length S RNA was established. The RT primer
used for reverse transcription binds to the
extreme termini of genomic and antigenomic S
and L RNA (Figure 3A). These termini are highly
conserved among all arenaviruses. Reverse
transcription was performed at a baseline
temperature of 50°C with short rises to 55°C and
60°C to resolve the stable RNA secondary
structure of the intergenic region. A mixture of
Taq and Pwo polymerases, the latter of which has
3'-5'-exonuclease (proofreading) activity, was
used in PCR. This enzyme combination can470 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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Figure 3. Reverse transcription (RT) and polymerase
chain reaction (PCR) amplification of full-length S
RNA. (A) Position of the RT and PCR primers at the
termini of S RNA. The stem-loop structure in the
intergenic region is schematically shown. (B)
Amplified S RNA of Lassa Josiah and LCMV
Armstrong virus separated in ethidium bromide-
stained agarose gel. S RNA was isolated from
supernatant of infected cells, and PCR was done with
primers PCR2-4. (C) S RNA of Lassa AV was amplified
in two RT-PCRs (a and b) and separated in ethidium
bromide-stained agarose gel. RNA was isolated from
serum, and PCR was performed with primers PCR2-4.
Quantification of Lassa virus RNA in the specimen by
endpoint titration with the 340-bp PCR assay showed
>106 S RNA molecules/mL serum.
amplify long templates with high fidelity and
sensitivity (25). Various primers and primer
combinations tested were found suitable for
efficient amplification of full-length S RNA of
Lassa virus and/or LCMV: PCR1; PCR2; PCR3;
PCR2 and PCR3; PCR2, PCR3, and PCR4; and
PCR5 (Figure 3B and data not shown). The PCR
primers were largely identical to the RT primer
but contained heterologous 5'-sequences that
allow cloning of the amplification product
through the restriction enzyme AscI. The 3'-end
of primer PCR1 exactly corresponded to that of
the RT primer, but primers PCR2 to PCR5
contained additional two or three nucleotides at
their 3'-end. These nucleotides were added to
reduce or prevent amplification of shorter
products generated by mispriming during
reverse transcription. Although the 3'-nucle-
otides of primers PCR2 and PCR3 did not
perfectly fit onto both termini of Lassa virus S
RNA, each primer alone was able to amplify the
full-length fragment (data not shown). This
feature, which may facilitate amplification of
strains with mutations in the primer binding site,
can be explained by the 3'-5'-exonuclease activity
of Pwo polymerase, which degrades primers and
corrects 3'-mismatches (26). In conclusion, we
developed an RT-PCR protocol allowing rapid
molecular characterization of S RNA of Lassa
virus and LCMV isolates. Because of the high
conservation of the primer binding sites, the
protocol may also be applied to other arenaviruses.
Sequence Determination of S RNA of
Lassa AV and Comparison with
Lassa Josiah and Nigeria
S RNA was isolated from the patient’s serum
and amplified in two RT-PCRs with the primer
combination PCR2, PCR3, and PCR4. Both
reactions showed a major product at the 3.5-kb
position (Figure 3C), indicating that the
predominant virus population contained full-
length S RNA. Some minor species in the 1.5- to 3-
kb size range may represent naturally occurring
RNA, with deletion as occasionally seen in
arenavirus-infected cell cultures (27), or artifact
fragments generated during RT-PCR. The PCR
products were purified, pooled, and sequenced.
The S RNA sequence was confirmed by
sequencing the 340-bp PCR fragment produced
by primers 36E2 and 80F2. The overlapping
sequences were completely identical. The
sequence was sent to GenBank and was assigned
accession number AF246121.
Alignment of the S RNA sequence of strain
Josiah with that of strains AV and Nigeria
showed considerable variability among the threeVol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 471
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strains (Figure 4). The highest frequency of
nucleotide changes, deletions, and insertions was
observed at the 3'- and 5'-noncoding regions just
upstream of the GPC and NP start codons on the
genomic and antigenomic strands, respectively
(position 25-55 and 3303-3365). Essentially no
Figure 4. Alignment of the genomic S RNA sequences of Lassa Josiah, AV, and Nigeria (sequences 1, 2, and 3,
respectively). The 3'- and 5'-noncoding regions and the intergenic region are separated from the coding regions by
vertical bars. Long vertical lines on the left mark the GPC and NP coding regions. Third base positions are marked
by a line of dots above each coding region. The GPC and NP start codons are underlined. The stem of the stem-loop
structure is underlined by a double line, while the loop is underlined by a dotted line. The RT primer binding sites
are indicated by slashes. Inserted nucleotides are shown above the sequence with the position of insertion
indicated by a vertical line. The S RNA sequence of strain AV was sent to GenBank and was assigned the accession
number AF246121.472 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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Table. Nucleotide and amino acid differences between
Lassa strains in S RNA coding regions
% Changes at
3rd codon
%   positions %
  Nucleotide    per total  Amino acid
difference in: changes in: difference in:
Strainsa GPC  NP GPC  NP GPC NP
AV vs. JOS 16.5 19.6 84.4 81.5 5.1 6.0
AV vs. NIG 20.3 21.3 83.7 78.3 6.7 8.1
NIG vs. JOS 19.2 22.4 83.7 77.1 6.9 8.9
aAV, strain AV; JOS, strain Josiah; NIG, strain Nigeria;
GPC = glycoprotein precursor protein; NP = nucleoprotein.
Figure 5. Alignment of the GPC and NP amino acid sequences of Lassa Josiah, AV, and Nigeria (sequences 1, 2,
and 3, respectively). B-cell epitopes [GPC 119-133 (28), GPC 124-176 (28), GPC 364-376 (29), NP 123-127 (31)],
T-cell epitopes (17), and the putative GPC cleavage site (30) are doubly underlined. Dots above the GPC sequence
mark potential N-linked glycosylation sites. Inserted amino acids are shown above the sequence with the position
of insertion indicated by a vertical line.
nucleotide was conserved in these regions or in a
short sequence in the intergenic region between
the GPC stop codon and the beginning of the RNA
stem-loop structure (position 1532-1540). In
contrast to these regions, the RNA stem-loop
structure (position 1545-1586) was highly
conserved, with no changes in the stem and little
variability in the loop. The NP and GPC coding
regions differed among the three strains by
approximately 20%, almost exclusively because
of nucleotide exchanges (Table). The partial NP
gene sequence of strain LP differed by 25% from
that of strain AV. The mutations were scattered
over entire coding regions except for short
conserved stretches. The most prominent feature
of this variability was the high number of
changes at third codon positions, which ac-
counted for approximately 80% of all nucleotide
differences (Table). The amino acid variability
was considerably lower (5%-9%) than the
variability at the nucleotide level (Table). The
degree of nucleotide and amino acid sequence
divergence was slightly higher in NP than in
GPC. Alignment of the GPC amino acid
sequences showed differences at the N-terminus
and within as well as in the vicinity of the B-cell
epitopes (Figure 5) (28,29). The putative GP1/GP2Vol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 473
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Figure 6. Phylogenetic analysis of Old World
arenaviruses, including Lassa AV. The tree was
computed for an NP gene fragment by using the
neighbor-joining method. Bootstrap support (in %) is
indicated at the respective branch. The same topology
and similar bootstrap values, except for the terminal
lymphocytic choriomeningitis virus branches, were
obtained by using the maximum likelihood method.
Tacaribe virus belonging to the New World
arenaviruses was used as outgroup to root the tree.
cleavage site (30) was completely conserved, as
were potential N-linked glycosylation sites, with
the exception of an additional site in Lassa AV
and Nigeria at position 272. In NP, two clusters of
amino acid variability (position 43-60 and 340-
353) were both characterized by a high number of
glycine residues at different positions in the
three strains (Figure 5). The mapped NP B-cell
epitope (31) was conserved, and only a few
changes occurred in the T-cell epitopes recently
identified in NP (32).
The phylogenetic relationship of Lassa AV to
known Old World arenaviruses as well as to the
other Lassa strains was analyzed by using partial
NP gene sequences. Strain AV segregated with
all Lassa strains into a single Lassa group with
100% bootstrap support and was placed in sister
relationship with strain Josiah (Figure 6). The
latter relationship was confirmed in analyzing
the full-length coding regions with 65%/61% (NJ/
ML analysis) bootstrap support for the GPC gene
and 94%/97% (NJ/ML analysis) bootstrap
support for the NP gene.
Conclusions
The complete S RNA sequences of three
Lassa virus strains—Nigeria (16), Josiah (15),
and AV—are now known. All three full-length
sequences, as well as the partial S RNA sequence
of strain LP (11), differ considerably, suggesting
that Lassa viruses comprise a monophyletic yet
genetically diverse group. Strain AV appears to
be phylogenetically most closely related to strain
Josiah. Prominent features of this variability are
a high number of substitutions at third-base
positions, a high degree of divergence at the 3'-
and 5'-noncoding regions just upstream of the NP
and GPC start codons, but conservation of the
intergenic stem-loop as well as the 19-nucleotide
termini, which are conserved among all
arenaviruses. Conservation of these termini in
strain AV was not directly demonstrated in our
study but was suggested by the efficient reverse
transcription and amplification with primers
binding to these ends. The divergence of the 3'-
and 5'-noncoding regions (excluding the con-
served termini) indicates either that their
function does not depend on a specific primary
sequence or that the functional variability of
these elements has no major impact on the Lassa
virus life cycle. These sequences correspond to
the 5'-untranslated regions on the NP and GPC
transcripts. Variability in these regions, espe-
cially in the so-called KOZAK sequence around
the start codon (33), may influence efficiency of
translation initiation and, thus, protein expres-
sion and virus production. Mutations in
noncoding regions may eventually explain
pathogenic differences among Lassa virus
strains (12), as they have in other viruses (34-36).
In contrast to the 3'- and 5'-noncoding regions,
the RNA stem-loop structure was highly
conserved, suggesting that this element does not
allow modification without seriously affecting
Lassa virus replication. Of the other arenaviruses,
only Mopeia virus has stem-loop sequences in
common with Lassa virus (37), which may be one
reason that both viruses can form stable
reassortants (38). The diverse geographic origins
of three of the four prototype strains (LP and
Nigeria are both of Nigerian origin) and the
relatedness of isolates circulating within an area474 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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(13) suggest geographic clustering of Lassa virus
strains. Genetic differences among Mastomys
species of several regions of West Africa may
have led to selection of subspecies-specific Lassa
strains. Alternatively, different Lassa strains
may have evolved in genetically identical
Mastomys populations, which are geographically
separated because of lack of migration.
The high degree of variability poses problems
for the design of diagnostic PCR and sequencing
primers. Most of our sequencing primers that
were designed on the basis of sequences of strain
Josiah and Nigeria failed to anneal to the new
strain as a result of several mutations in their
binding sites. In addition, the binding site of
primer 80F2 (18), which had been designed for
diagnostics on the basis of nine Lassa sequences,
contained three mutations. As they affected only
the 5' half of the primer, performance of the PCR
was not seriously reduced, confirming its
usefulness for diagnostic purposes. The full-
length S RNA RT-PCR may be an alternative for
diagnostics because of its highly conserved
primer binding sites, although its sensitivity may
be somewhat lower.
Phylogenetic analysis showed minor differ-
ences in the tree topology of the Old World
arenaviruses in comparison to previous analysis
(11). In our analysis, Mobala and Mopeia viruses
were placed in close relationship, while the
previous study indicated that Mobala is most
closely related with Lassa virus. However, in
both studies, bootstrap support was low and the
tree topology depended on the inclusion of
changes at the third codon position  (11).
Placement of Lassa Nigeria, Josiah, and LP
differed in both studies in a similar manner.
Analysis of additional sequences may be required
to elucidate the exact phylogenetic relationship
among Mopeia, Mobala, and Lassa viruses, as
well as between Lassa virus strains Nigeria,
Josiah, and LP.
Development of a vaccine against Lassa virus
is a main goal of research (39). Protective
immunity is achieved in animals by vaccination
with Lassa NP or GPC-expressing vaccinia virus
and seems to be mediated by the T-cell response
(40-42). However, whether a recombinant
vaccine based on a single Lassa protein of a
specific strain cross-protects against heterolo-
gous Lassa strains has not yet been studied.
Recently, several epitopes recognized by Lassa
NP-specific CD4+ T-cell clones of one person were
mapped (32). Most of them are conserved in at
least two of three Lassa strains (Josiah, Nigeria,
and AV). The relatively large number of T-cell
epitopes recognized, as well as their partial
conservation, suggests a level of T-cell cross-
reactivity that might be sufficient for cross-
protection against heterologous strains after
immunization with NP-based vaccines. This view
is supported by experiments with Lassa GPC-
based vaccines, which indicate CD4+ T-cell-
mediated cross-protection even against LCMV
(43). Use of the new Lassa virus strain as
heterologous challenge virus after immunization
with recombinant vaccines, as well as use of its
proteins in in-vitro assays to study T-cell cross-
reactivity, may enhance our understanding of
Lassa virus-specific cross-protective immunity.
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